Medulloblastoma subgroups remain stable across primary and metastatic compartments

scientific article

Medulloblastoma subgroups remain stable across primary and metastatic compartments is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1007/S00401-015-1389-0
P932PMC publication ID4333718
P698PubMed publication ID25689980
P5875ResearchGate publication ID272512874

P50authorJames RutkaQ17156655
Tobey J MacDonaldQ99550976
Livia GarziaQ114421153
Adrian M DubucQ114529448
Timothy E Van MeterQ114529465
Patryk SkowronQ114726875
Caitlin HoffmanQ114726876
Benjamin Haibe-KainsQ38639014
Stefan M. PfisterQ39183179
Vijay RamaswamyQ43153342
Marc RemkeQ43153350
Stephen C MackQ55459128
Xin WangQ55459131
Deena M. A. GendooQ61312308
Eric BouffetQ64584887
Cynthia HawkinsQ64584929
Betty LuuQ87124261
Charles G EberhartQ87148391
David LydenQ87823035
David ZagzagQ88011784
Michael D. TaylorQ88072573
Andrey KorshunovQ89166780
Yoon-Jae ChoQ90317000
Paul A NorthcottQ91826566
P2093author name stringBorja López
Xiaochong Wu
Xiao-Nan Li
John Peacock
Florence Cavalli
P2860cites workMolecular subgroups of medulloblastoma: the current consensusQ24615271
Summaries of Affymetrix GeneChip probe level dataQ27860888
Integrative genomic analysis of medulloblastoma identifies a molecular subgroup that drives poor clinical outcomeQ28298987
Medulloblastoma: tumorigenesis, current clinical paradigm, and efforts to improve risk stratificationQ28299667
Subtypes of medulloblastoma have distinct developmental originsQ28300616
Diagnosis of multiple cancer types by shrunken centroids of gene expressionQ29615528
Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastomaQ29615604
CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2005-2009.Q30447832
Integrated genomics identifies five medulloblastoma subtypes with distinct genetic profiles, pathway signatures and clinicopathological featuresQ33366431
Molecular subgroups of medulloblastoma: an international meta-analysis of transcriptome, genetic aberrations, and clinical data of WNT, SHH, Group 3, and Group 4 medulloblastomasQ34167499
FSTL5 is a marker of poor prognosis in non-WNT/non-SHH medulloblastomaQ34215755
Mutational analysis reveals the origin and therapy-driven evolution of recurrent gliomaQ34391844
An animal model of MYC-driven medulloblastomaQ35774418
Clonal selection drives genetic divergence of metastatic medulloblastomaQ35784926
Rapid, reliable, and reproducible molecular sub-grouping of clinical medulloblastoma samplesQ35837393
Outcome of children with metastatic medulloblastoma treated with carboplatin during craniospinal radiotherapy: a Children's Oncology Group Phase I/II studyQ36025964
Intratumor heterogeneity in human glioblastoma reflects cancer evolutionary dynamics.Q36673354
Medulloblastoma comprises four distinct molecular variantsQ36920479
High-risk medulloblastoma: a pediatric oncology group randomized trial of chemotherapy before or after radiation therapy (POG 9031)Q37066730
Metagenes and molecular pattern discovery using matrix factorizationQ37356699
Medulloblastomics: the end of the beginningQ37469904
Recurrence patterns across medulloblastoma subgroups: an integrated clinical and molecular analysisQ37636027
FISH and chips: the recipe for improved prognostication and outcomes for children with medulloblastoma.Q37971394
Intertumoral and intratumoral heterogeneity as a barrier for effective treatment of medulloblastoma.Q38120467
Decoding the regulatory landscape of medulloblastoma using DNA methylation sequencingQ38993103
Genomics identifies medulloblastoma subgroups that are enriched for specific genetic alterationsQ40339027
A mouse model of the most aggressive subgroup of human medulloblastomaQ41484437
Robust molecular subgrouping and copy-number profiling of medulloblastoma from small amounts of archival tumour material using high-density DNA methylation arraysQ43153279
Hyperfractionated accelerated radiotherapy in the Milan strategy for metastatic medulloblastomaQ46201996
Adult medulloblastoma comprises three major molecular variants.Q55463035
Phase III study of craniospinal radiation therapy followed by adjuvant chemotherapy for newly diagnosed average-risk medulloblastoma.Q55469539
P4510describes a project that useslimmaQ112236343
P433issue3
P921main subjectmedulloblastomaQ1333608
P304page(s)449-457
P577publication date2015-01-21
P1433published inActa NeuropathologicaQ343168
P1476titleMedulloblastoma subgroups remain stable across primary and metastatic compartments
P478volume129

Reverse relations

cites work (P2860)
Q39346476"miR miR on the wall, who's the most malignant medulloblastoma miR of them all?"
Q50422142A Hematogenous Route for Medulloblastoma Leptomeningeal Metastases.
Q47851564ATOH1 Promotes Leptomeningeal Dissemination and Metastasis of Sonic Hedgehog Subgroup Medulloblastomas.
Q41694115Added value of diffusion weighted imaging in pediatric central nervous system embryonal tumors surveillance
Q48116800Advances in Genomics Explain Medulloblastoma Behavior at the Bedside.
Q57805008BMI1 is a therapeutic target in recurrent medulloblastoma
Q35710253Characterization of medulloblastoma in Fanconi Anemia: a novel mutation in the BRCA2 gene and SHH molecular subgroup
Q43056671Characterizing temporal genomic heterogeneity in pediatric high-grade gliomas
Q47282131Childhood Medulloblastoma: Current Therapies, Emerging Molecular Landscape and Newer Therapeutic Insights.
Q37073617Divergent clonal selection dominates medulloblastoma at recurrence
Q33572502Establishment and characterization of an orthotopic patient-derived Group 3 medulloblastoma model for preclinical drug evaluation.
Q38652681Evolving molecular era of childhood medulloblastoma: time to revisit therapy
Q36142459Genetic and molecular alterations across medulloblastoma subgroups
Q53622562Histological subtype of medulloblastoma frequently changes upon recurrence.
Q47816782Identification of GPC2 as an Oncoprotein and Candidate Immunotherapeutic Target in High-Risk Neuroblastoma.
Q94527860Immunotherapy for Medulloblastoma: Current Perspectives
Q33903199Investigation of brain tissue infiltration by medulloblastoma cells in an ex vivo model
Q55452816MRI features as a helpful tool to predict the molecular subgroups of medulloblastoma: state of the art.
Q86064194Medulloblastoma
Q54954567Medulloblastoma in the Molecular Era.
Q38954656Medulloblastoma initiation and spread: Where neurodevelopment, microenvironment and cancer cross pathways
Q39225738Medulloblastoma: Molecular Classification-Based Personal Therapeutics
Q38791824Medulloblastoma: Tumor Biology and Relevance to Treatment and Prognosis Paradigm
Q39446793Medulloblastoma: experimental models and reality
Q39134342Modern management of medulloblastoma: Molecular classification, outcomes, and the role of surgery
Q37573700Molecular Classification of Medulloblastoma
Q92865416Molecular stratifications, biomarker candidates and new therapeutic options in current medulloblastoma treatment approaches
Q36716785Mutations in chromatin machinery and pediatric high-grade glioma
Q92705351Preclinical Models of Craniospinal Irradiation for Medulloblastoma
Q55403358Recurrent extraneural sonic hedgehog medulloblastoma exhibiting sustained response to vismodegib and temozolomide monotherapies and inter-metastatic molecular heterogeneity at progression.
Q37250411Relapse patterns and outcome after relapse in standard risk medulloblastoma: a report from the HIT-SIOP-PNET4 study
Q88993176Rethinking medulloblastoma from a targeted therapeutics perspective
Q91780113Salvage Therapy for Childhood Medulloblastoma: A Single Center Experience
Q41860267Silencing of Urothelial Carcinoma Associated 1 Inhibits the Proliferation and Migration of Medulloblastoma Cells
Q34552042Targeting Epigenetic Pathways in the Treatment of Pediatric Diffuse (High Grade) Gliomas
Q98784812Wnt activation as a therapeutic strategy in medulloblastoma